The headline is broadly defensible, but the qualifications matter. Effect sizes vary by population, the strongest claims rest on shorter trials, and credible voices push back on how it's typically framed.
whereas like 60% of the mice that didn't get rapid mice now the 2009 study that kicked all this off actually showed a greater survival benefit in the female mice didn't it that's right so I think and again this is a guess because I don't actually have the data to back it up my guess is that because we push the dose so high we might have actually taken it too far in the female
Every Sunday: the week’s new conflicts and verdict changes — and nothing else.
Native comments, Twitter mentions, and Reddit threads about this claim — surfaced together so the conversation isn't fragmented across platforms.
The "high risk" framing here is the right call. I've had three patients ask about rapa this month and none of them grasped the immunosuppression tradeoff until I walked them through it.
The PEARL trial framing in the dossier is the clearest writeup I've seen for a non-specialist. Worth linking from the AMA pages too.
I'm on 6mg/week, year two. Tracking IL-6, fasting glucose, lipids. Happy to share the spreadsheet if Whalespan wants longitudinal user data.
The dosing variance across the advocate camp is staggering. 3mg, 5mg, 8mg, biweekly, weekly… brief is right that "monitor or specialist only" is the responsible read.
the female mice had no difference in lifespan the mice the got rapamycin or didn't get rapamycin but they died with I want to say from but it's hard to say for sure what a mouse dies from they died with very different types of cancers so the female mice that had gotten this high dose of rapamycin for 3 months all had aggressive hematopoietic cancers
the female mice had no difference in lifespan the mice that got rapamycin or didn't get rapamycin but they died with very different types of cancers so the female mice that had gotten this high dose of rapamycin for 3 months all had aggressive hematopoiesis hmm whereas about I think it was about 30 or 40 percent of the vehicle treated mice so the in black 6 that's not an uncommon good but none of the rapamycin treated mice had non-dramatic kwatak cancers
Rapamycin extends median and maximum lifespan in mice across multiple lab strains and dosing protocols.
Rapamycin will extend human lifespan by 5+ years at standard weekly dosing.
Weekly rapamycin dosing in healthy adults shows favorable safety and immune markers in early observational data.
Chronic low-dose rapamycin imposes an immune trade-off that outweighs the longevity hypothesis for most healthy adults.
mTORC1 inhibition is the mechanistic backbone for rapamycin's healthspan effects in mammals.
The PEARL trial showed an acceptable 48-week safety profile in healthy adults on weekly rapamycin.